Abstract:1,2-Cyclohexanedicarboxylic acid, 1,2-diisononylester (DINCH), a polyvinyl chloride plasticizer, has food, beverage, and medical device applications that may result in general population exposure. Although no apparent toxicity information in humans was identified, there is a substantial data set in lab animals to serve as the basis of hazard identification for DINCH. Target tissues associated with repeated dietary DINCH exposure in lab animals included liver, kidney, and thyroid and mammary glands. In contrast… Show more
“…Rubin (1975) and Schulz et al (1975). Bhat et al (2014) reported what had been reviewed by the independent National Sanitation Foundation (NSF) Health advisory board and by regulatory bodies such as EFSA and NICNAS on the toxicology of Hexamoll ® DINCH ® . They all concluded that target organs from oral administration were the thyroid gland and the kidneys.…”
Section: Metabolite Determinationmentioning
confidence: 99%
“…The issues for substitution range from ease of "drop-in" to efficacy for blood storage. Hexamoll ® DINCH ® was developed as a substitute plasticizer for "sensitive" applications: it has a low toxicity; is not considered to be an endocrine-active substance (Furr et al, 2014); and has a low migration from PVC (Bhat et al, 2014). Oral exposure was associated in rats with induction of liver enzymes that are believed to have altered circulating thyroid gland hormones, resulting in an enlarged thyroid gland; this effect is a secondary mechanism that is not considered to be relevant for humans (European Food Safety Authority, 2006).…”
Alternative plasticizers to di(2-ethylhexyl) phthalate (DEHP) for blood bags have been sought for many years. Cyclohexane-1,2-dicarboxylic acid, diisononylester (Hexamoll(®) DINCH(®)) is an alternative that has been evaluated in preliminary studies for compatibility and efficacy to preserve whole blood. While Hexamoll(®) DINCH(®) has an extensive database for mammalian toxicity via oral administration, data were needed to evaluate toxicity from intravenous (IV) administration to support the use of the plasticizer Hexamoll(®) DINCH(®) in blood bags. A series of studies was performed by slow IV injection or IV infusion of Hexamoll(®) DINCH(®), a highly viscous, hydrophobic substance, suspended in Intralipid(®) 20% (20% intravenous fat emulsion). Rats were injected once, followed by 14 days of recovery; injected daily for 5 days followed by 5 days of recovery, or infused for 29 days (4h/day) followed by 14 days of recovery. Dose levels were 0, 62, 125, and 250-300mg/kg body weight/day. These dose levels represent the limits of suspension and far exceed any anticipated exposures from migration out of plasticized blood bags. Animals were observed for signs of toxicity; body weight and feed consumption were measured; blood collected for clinical chemistry and hematology; and tissues collected and processed for histopathology. Special emphasis was placed on evaluating endpoints and tissues that are commonly associated with plasticizer exposure in rodents. Urine was collected during the 4-week study to quantify urinary metabolites of Hexamoll(®) DINCH(®). The results of the studies indicate that no substance-related toxicity occurred: no effects on behavior, no effects on organ weight, no effect on serum chemistry including thyroid hormones; and no effect on major organs, especially no testicular toxicity and no indication for peroxisome proliferation in the liver. The only effects seen were petechia and granulomas related to dissipation of suspended Hexamoll(®) DINCH(®) in the aqueous environment of the blood. However, the results of metabolite analyses demonstrate that Hexamoll(®) DINCH(®) was bioavailable. Therefore, based on the lack of Hexamoll(®) DINCH(®)-related systemic toxicity with the exception of the physical limitations, the no-observed-adverse-effect level for parenterally administered Hexamoll(®) DINCH(®) is considered to be 300mg/kg bw/day.
“…Rubin (1975) and Schulz et al (1975). Bhat et al (2014) reported what had been reviewed by the independent National Sanitation Foundation (NSF) Health advisory board and by regulatory bodies such as EFSA and NICNAS on the toxicology of Hexamoll ® DINCH ® . They all concluded that target organs from oral administration were the thyroid gland and the kidneys.…”
Section: Metabolite Determinationmentioning
confidence: 99%
“…The issues for substitution range from ease of "drop-in" to efficacy for blood storage. Hexamoll ® DINCH ® was developed as a substitute plasticizer for "sensitive" applications: it has a low toxicity; is not considered to be an endocrine-active substance (Furr et al, 2014); and has a low migration from PVC (Bhat et al, 2014). Oral exposure was associated in rats with induction of liver enzymes that are believed to have altered circulating thyroid gland hormones, resulting in an enlarged thyroid gland; this effect is a secondary mechanism that is not considered to be relevant for humans (European Food Safety Authority, 2006).…”
Alternative plasticizers to di(2-ethylhexyl) phthalate (DEHP) for blood bags have been sought for many years. Cyclohexane-1,2-dicarboxylic acid, diisononylester (Hexamoll(®) DINCH(®)) is an alternative that has been evaluated in preliminary studies for compatibility and efficacy to preserve whole blood. While Hexamoll(®) DINCH(®) has an extensive database for mammalian toxicity via oral administration, data were needed to evaluate toxicity from intravenous (IV) administration to support the use of the plasticizer Hexamoll(®) DINCH(®) in blood bags. A series of studies was performed by slow IV injection or IV infusion of Hexamoll(®) DINCH(®), a highly viscous, hydrophobic substance, suspended in Intralipid(®) 20% (20% intravenous fat emulsion). Rats were injected once, followed by 14 days of recovery; injected daily for 5 days followed by 5 days of recovery, or infused for 29 days (4h/day) followed by 14 days of recovery. Dose levels were 0, 62, 125, and 250-300mg/kg body weight/day. These dose levels represent the limits of suspension and far exceed any anticipated exposures from migration out of plasticized blood bags. Animals were observed for signs of toxicity; body weight and feed consumption were measured; blood collected for clinical chemistry and hematology; and tissues collected and processed for histopathology. Special emphasis was placed on evaluating endpoints and tissues that are commonly associated with plasticizer exposure in rodents. Urine was collected during the 4-week study to quantify urinary metabolites of Hexamoll(®) DINCH(®). The results of the studies indicate that no substance-related toxicity occurred: no effects on behavior, no effects on organ weight, no effect on serum chemistry including thyroid hormones; and no effect on major organs, especially no testicular toxicity and no indication for peroxisome proliferation in the liver. The only effects seen were petechia and granulomas related to dissipation of suspended Hexamoll(®) DINCH(®) in the aqueous environment of the blood. However, the results of metabolite analyses demonstrate that Hexamoll(®) DINCH(®) was bioavailable. Therefore, based on the lack of Hexamoll(®) DINCH(®)-related systemic toxicity with the exception of the physical limitations, the no-observed-adverse-effect level for parenterally administered Hexamoll(®) DINCH(®) is considered to be 300mg/kg bw/day.
“…Zusammenfassende Darstellungen der relevanten toxikologischen Untersuchungen und ihre Bewertungen finden sich in dem Bericht der europäischen Behör-de für Lebensmittelsicherheit [16], in der Dokumentation der australischen Chemikalienbehörde (NICNAS) [19] sowie in der Publikation von Bath et al [20]. Die Verwendung von DINCH in Medizinprodukten wurde durch ein wissenschaftliches Expertengremium der EU Kommission bewertet [4].…”
“…Die 2-Generationen-Studie wurde sowohl von der EFSA [16] wie auch von Bhat et al [20] einer Neubewertung unterworfen (s. Kap. 5).…”
Section: Tab 3)unclassified
“…Gemeinsam haben beide Ableitungen, dass jeweils ein Sicherheitsfaktor von 100 verwendet wurde. Ferner liegt eine aktuelle und ausführliche Ableitung für eine RfD von Bath et al [20] vor. Bewertungen der toxikologischen Daten durch weitere Gremien liegen vor, die Ableitungen von NOAEL-Werten werden nachfolgend dargestellt, TDI-Werte wurden jedoch nicht abgeleitet.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.